Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 16

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
-  
     - 
  
    Total cash equivalents 
    $18,975  
    $18,975  
    $-  
    $- 

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    December 31, 2024: 

    Cash equivalents 

    Treasury Bills 
    $10,260  
    $10,260  
    $             -  
    $             - 
  
    Money market fund 
     10,328  
     10,328  
     -  
     - 
  
    Total cash equivalents 
    $20,588  
    $20,588  
    $-  
    $- 

NOTE 6 – LEASE 

The Company leases office space in Florida from
a third party. The lease agreement has a 64-month term and commenced during the fourth quarter of 2021.

Below is a summary of the Company’s right-of-use
assets and liabilities:

  (in thousands, except years and rate)  March 31,  2025   December 31, 2024   Right-of-use asset  $278   $307                Operating lease, current liability  $146   $140   Long-term operating lease liability   201    244   Total lease liability  $347   $384                Weighted-average remaining lease term   2.0 years    2.3 years                Weighted-average discount rate   12.0%   12.0% 

13

NOTE 7 – RELATED PARTY TRANSACTIONS

UCL

At March
31, 2025 and December 31, 2024, the Company recorded a payable to UCL of $52,000 and $0, respectively, for medical research performed
on behalf of the Company. During the three months ended March 31, 2025 and 2024, the Company made no payments to UCL. UCL is a wholly
owned subsidiary of the University of London. The Company’s Chief Scientific and Manufacturing Officer is a professor at the University
of London.

Am